Last $6.98 USD
Change Today +0.22 / 3.25%
Volume 98.1K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kleanthis G. Xanthopoulos Ph.D.

Chief Executive Officer, President, Principal Financial & Accounting Officer and Director, Regulus Therapeutics Inc.
AgeTotal Calculated CompensationThis person is connected to 147 board members in 7 different organizations across 12 different industries.

See Board Relationships
55$2,641,363
As of Fiscal Year 2013

Background*

Dr. Kleanthis G. Xanthopoulos, Ph.D. has been the President and Chief Executive Officer of Regulus Therapeutics Inc., since January 2009. Dr. Xanthopoulos serves as Managing Director of Life Science Investments at Novera Optics, Inc. He serves as a Member of the Executive Board at BIOCOM, Inc. He Founded Sente, Inc. and served as its Chief Executive Officer and President. He served as the President and Chief Executive Officer of Regulus Therapeutics, LLC since joining ...

Read Full Background

Corporate Headquarters*

3545 John Hopkins Court
San Diego, California 92121

United States

Phone: 858-202-6300
Fax: --

Board Members Memberships*

Director
Former Director
Director
Founder and Director
Director
2000-2011
Former Director and Member of Audit Committee
2009-Present
Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
2011-Present
Chairman
2013-Present
Director
2013-2014
Former Director

Education*

MS
Stockholms universitet
PhD
Stockholms universitet
BS
University of Thessaloniki

Other Affiliations*

Annual Compensation*

Salary$600,000
Total Annual Compensation$600,000

Stock Options*

All Other Compensation$4,540

Total Compensation*

Total Annual Cash Compensation$964,540
Total Short Term Compensation$600,000
Other Long Term Compensation$4,540
Total Calculated Compensation$2,641,363
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $6.98 USD +0.22

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
4.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer and Interim Chief Operating Officer
Enzon Pharmaceuticals Inc.
$226.4K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$249.8K
Mark J. Ahn Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$664.9K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Compensation as of Fiscal Year 2012.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.